Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).

Psychopharmacology (Berl) 2017 Jun 1;234(11):1671-1681. Epub 2017 Mar 1.

Department of Pharmacology, Temple University School of Medicine, 3500 North Broad Street, Philadelphia, PA, 19140, USA.

Rationale: Metabotropic glutamate 2 and 3 (mGluR2/3) receptors are implicated in drug addiction as they limit excessive glutamate release during relapse. N-acetylaspartylglutamate (NAAG) is an endogenous mGluR2/3 agonist that is inactivated by the glutamate carboxypeptidase II (GCPII) enzyme. GCPII inhibitors, and NAAG itself, attenuate cocaine-seeking behaviors. However, their effects on the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) have not been examined.

Objectives: We determined whether withdrawal following repeated MDPV administration alters GCPII expression in corticolimbic regions. We also examined whether a GCPII inhibitor (2-(phosphonomethyl)-pentanedioic acid (2-PMPA)), and NAAG, reduce the rewarding and locomotor-stimulant effects of MDPV in rats.

Methods: GCPII was assessed following repeated MDPV exposure (7 days). The effects of 2-PMPA and NAAG on acute MDPV-induced hyperactivity were determined using a locomotor test. We also examined the inhibitory effects of 2-PMPA and NAAG on MDPV-induced place preference, and whether the mGluR2/3 antagonist LY341495 could prevent these effects.

Results: MDPV withdrawal reduced GCPII expression in the prefrontal cortex. Systemic injection of 2-PMPA (100 mg/kg) did not affect the hyperactivity produced by MDPV (0.5-3 mg/kg). However, nasal administration of NAAG did reduce MDPV-induced ambulation, but only at the highest dose (500 μg/10 μl). We also showed that 2-PMPA (10-30 mg/kg) and NAAG (10-500 μg/10 μl) dose-dependently attenuated MDPV place preference, and that the effect of NAAG was blocked by LY341495 (3 mg/kg).

Conclusions: These findings demonstrate that MDPV withdrawal produces dysregulation in the endogenous NAAG-GCPII signaling pathway in corticolimbic circuitry. Systemic administration of the GCPII inhibitor 2-PMPA, or NAAG, attenuates MDPV reward.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00213-017-4568-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433920PMC
June 2017
9 Reads

Publication Analysis

Top Keywords

2-pmpa naag
16
gcpii inhibitor
12
mdpv
10
naag
10
synthetic cathinone
8
mdpv withdrawal
8
effects synthetic
8
repeated mdpv
8
effects 2-pmpa
8
gcpii expression
8
place preference
8
n-acetylaspartylglutamate naag
8
glutamate carboxypeptidase
8
gcpii
8
carboxypeptidase gcpii
8
inhibitor 2-pmpa
8
naag reduce
8
2-pmpa
7
effects
5
preference mglur2/3
4

Similar Publications